feed,title,long_url,short_url
Benzinga,Intertrust reports Q4 and FY 2020 results,https://www.benzinga.com/pressreleases/21/02/g19631645/intertrust-reports-q4-and-fy-2020-results,https://j.mp/3ad7uLv
Benzinga,Basilea reports derazantinib/PD-L1 checkpoint inhibitor combination results from dose-finding part of FIDES-02 study in patients with solid tumors at ASCO GU symposium,https://www.benzinga.com/pressreleases/21/02/g19631644/basilea-reports-derazantinibpd-l1-checkpoint-inhibitor-combination-results-from-dose-finding-part-,https://j.mp/3d4O4Kt
Benzinga,Basilea reports derazantinib/PD-L1 checkpoint inhibitor combination results from dose-finding part of FIDES-02 study in patients with solid tumors at ASCO GU symposium,https://www.benzinga.com/pressreleases/21/02/tr19631647/basilea-reports-derazantinibpd-l1-checkpoint-inhibitor-combination-results-from-dose-finding-part,https://j.mp/2LIN9Eh
Benzinga,Intertrust reports Q4 and FY 2020 results,https://www.benzinga.com/pressreleases/21/02/tr19631646/intertrust-reports-q4-and-fy-2020-results,https://j.mp/2Z9caM1
